Peter Marks suggests that cell and gene therapy, as well as other product sponsors will be seeking help with clinical trials stalled by the pandemic.
While the coronavirus-related workload already is taxing the US Food and Drug Administration staff, Peter Marks worries a post-pandemic bolus may add to the workload crunch.
The director of the FDA’s Center for Biologics Evaluation and Research said 11 June during a session at the Biotechnology...
In what could amount to a de facto enforcement mechanism, the new draft guidance also “strongly encourages” sponsors to share details about their diversity action plan and enrollment goals with the public.
Long-term follow-up requirements have taken a conservative approach but could be ripe for re-examination and global harmonization given the years of experience with the products, Kite Pharma executive director says; former FDA gene/cell therapy office head Wilson Bryan calls for elimination of the classwide REMS.
Program for collaborative reviews of gene therapy applications is getting under way with the European Medicines Agency. After launch, the pilot could be expanded to earlier discussions around CMC and pharm/tox data requirements, FDA’s Nicole Verdun said.
